Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Prostatic Neoplasms 2Tuberous Sclerosis 1Recurrence 1Polycystic Ovary Syndrome 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Focal Cortical Dysplasia 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumours 1Advanced Solid Tumors 1

Interventions

pembrolizumab 3Carboplatin 3Nivolumab 2Injections 2Docetaxel 2Cisplatin 2BMS-753493 2zimberelimab 1urelumab 1tislelizumab 1tesetaxel 1spartalizumab 1olaparib 1liposomal doxorubicin 1linifanib 1lenvatinib 1ixabepilone 1durvalumab 1avelumab 1avdoralimab 1adavosertib 1TAS-119 1Rifampin 1N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 1Maximum Tolerated Dose 1Linoleic Acids, Conjugated 1Lapatinib 1Itraconazole 1Irinotecan 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Solid Tumors × Itraconazole × Clear all
NCT04312282 2021-07-28

The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors

Odonate Therapeutics, Inc.

Phase 1 Terminated
93 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡